Another 25 Indonesian hajj pilgrims die
Thursday, December 3, 2009 09:27
Jedda (ANTARA News) - Twenty-five more Indonesian hajj pilgrims have died since Sunday, bringing to 161 the number of the country`s hajj pilgrims who died during their journey of worship in Saudi Arabia this year.
Some of the hajj pilgrims died of heart disease and respiratory failure, the Religious Affairs Ministry`s integrated hajj communications system (Siskohat) unit said on Thursday.
More than 196,100 Indonesians performed hajj pilgrimage this year. They were flown to the Holy Land in 475 batches.
Islam obliges its adherents who can afford to it to perform hajj pilgrimage once during their lifetime.(*)
http://www.antara.co.id/en/news/1259807247/another-25-indonesian-hajj-pilgrims-die
Severely ill hospital patients need swine flu drug boost: WHO
(AFP) – 7 hours ago
http://www.google.com/hostednews/afp/article/ALeqM5jJzZct5LIo0gwhRXTIpGH-uzUltg
GENEVA — The World Health Organisation on Wednesday recommended boosted antiviral treatment for hospital patients with severely weakened immune systems who contract swine flu, following recent clusters of Tamiflu resistance.
Although the WHO said there was no evidence that the two clusters found in Wales and in North Carolina marked a wider public health threat, it reiterated calls for vigilance and modified treatment advice for the frontline flu drug.
In the two clusters found in single hospital wards in October and November, patients — eight in Wales and four in the United States — were suspected of infecting each other with the Tamiflu-resistant strain.
In such patients with suppressed immune systems, “standard treatment doses and duration for treatment with oseltamivir (Tamiflu) are unlikely to be sufficient,” the WHO said in a briefing note posted on its website.
“Though clinical judgement is important, doses may need to be increased and continued, without interruption, for the duration of acute illness,” it added.
The UN health agency also recommended that the alternative drug to Tamiflu, Zanamivir, “should be considered as the treatment of choice for patients who develop prolonged influenza illness despite treatment with oseltamivir.”
Oseltamivir is sold by pharmaceutical company Novartis under the brand name Tamiflu, while GlaxoSmithKline’s Zanamivir is marketed as Relenza.
The WHO repeated the need for “vigilant monitoring” of the Tamiflu-resistant flu virus.
“Experience with seasonal influenza viruses shows that resistant viruses can quickly spread within the general population and become established, rendering one or more antiviral drugs ineffective,” it cautioned.
Within the past two weeks, the number of documented cases of Tamiflu resistance in those who have contracted A(H1N1) flu has risen from 57 to 96, according to the global health watchdog.
About one third occurred in patients whose immune systems were severely weakened by blood problems, aggressive chemotherapy for cancer, or post-transplant treatment.